Aradigm
HomeAboutProductsTechnologiesInvestorsCareers
Press Releases

Press Releases

All Releases
Aradigm Receives Complete Response Letter from the FDA for Linhaliq NDA
Jan 29, 2018
HAYWARD, Calif. --(BUSINESS WIRE)--Jan. 29, 2018-- Aradigm Corporation (NASDAQ: ARDM) (the “Company”) today announces that it received a Complete Response Letter (CRL) from the US Food and Drug Administration ( FDA ) regarding its New Drug Application (NDA) for Linhaliq™ as a treatment for
Aradigm Reports Results of FDA Advisory Committee Meeting on Linhaliq
Jan 11, 2018
HAYWARD, Calif. , Jan. 11, 2018 (GLOBE NEWSWIRE) -- Aradigm Corporation (NASDAQ:ARDM) (the "Company") today announces that the Antimicrobial Drugs Advisory Committee (ADAC) of the US Food and Drug Administration (FDA) did not recommend approval for Linhaliq™ as a treatment for non-cystic fibrosis
Aradigm Announces FDA Advisory Committee Meeting for Linhaliq
Dec 01, 2017
Meeting Scheduled for January 11, 2018 HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced that a meeting of the Antimicrobial Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has been scheduled for January 11, 2018 to review
Aradigm to Host Key Opinion Leader Meeting and Webcast on November 9 in New York City
Nov 07, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq: ARDM) (the "Company") announced today that it will host a Key Opinion Leader (KOL) Breakfast on the topic of Non-Cystic Fibrosis Bronchiectasis (NCFBE) on Thursday, November 9, 2017 from 8:00-9:30 am Eastern Time in New York, NY .
Aradigm Announces Third Quarter 2017 Financial Results
Nov 02, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2017 . The Company recorded $2.7 million in revenue in the third quarter of 2017 compared with $50,000 in revenue in the
Aradigm Regains Compliance with NASDAQ Listing Requirements
Oct 10, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced that it received notice from The NASDAQ Capital Market ("NASDAQ") indicating that the Company has regained compliance under NASDAQ Listing Rule 5550(a)(2) for continued listing on The
Aradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status
Sep 25, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug Application (NDA) for Linhaliq™ for the treatment of non-cystic fibrosis bronchiectasis
Aradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26
Sep 22, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) ("Aradigm" or the "Company") today announced that Aradigm management will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 , at 2:00 p.m. ET .
Aradigm to Host KOL Call on Infection Management in Non-Cystic Fibrosis Bronchiectasis Patients
Sep 15, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced that it will host a Key Opinion Leader (KOL) call on the topic of infection management in non-cystic fibrosis bronchiectasis (NCFBE) patients on Monday, September 18 at 11am Eastern Time .
Aradigm Announces Upcoming Data Presentations in Non-Cystic Fibrosis Bronchiectasis at the European Respiratory Society (ERS) 2017 Annual Congress
Sep 05, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ:ARDM) (the "Company") today announced the upcoming presentation of research at the European Respiratory Society (ERS) 2017 Annual Congress, the world's largest meeting of respiratory professionals, taking place in Milan, Italy from
Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections with Linhaliq
Aug 15, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- The National Institute of Allergy and Infectious Diseases (NIAID) and National Institutes of Health (NIH) awarded Aradigm Corporation (NASDAQ:ARDM) a Small Business Initiative Research (SBIR) grant to investigate the treatment of two pulmonary non-tuberculous
Aradigm Announces Second Quarter 2017 Financial Results
Aug 10, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced financial results for the second quarter and six months ended June 30, 2017 . The Company recorded $7.7 million in revenue in the second quarter of 2017 compared with $14,000 in revenue in the
Aradigm Submits New Drug Application (NDA) to FDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
Jul 27, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq™ for the treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic
Aradigm Announces First Quarter 2017 Financial Results
May 15, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ:ARDM) (the "Company") today announced financial results for the first quarter and three months ended March 31, 2017 . First Quarter 2017 Financial Results The Company recorded $1.7 million in revenue in the first quarter of 2017
Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results
Mar 28, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ: ARDM) (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2016 . Fourth Quarter 2016 Results The Company recorded $125,000 in revenue in the fourth quarter of 2016 compared with
Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13
Feb 09, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present at the 19 th Annual BIO CEO & Investor Conference 2017 on Monday, February 13, 2017 , at 1:30 p.m. ET .
Aradigm to Present at 9th Annual Biotech Showcase Conference on January 9
Jan 06, 2017
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda , Ph.D., will present an overview of the Company at the 9 th Annual Biotech Showcase Conference on Monday, January 9, 2017 , at 5:00 p.m.
Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections with Pseudomonas aeruginosa
Dec 01, 2016
Company to host conference call at 4:30 pm ET today HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ:ARDM) (the "Company") today announced top-line results from its two Phase 3 clinical trials (ORBIT-3 and ORBIT-4) evaluating the safety and efficacy of Pulmaquin®, the Company's
Aradigm to Present at the Stifel 2016 Healthcare Conference on November 16
Nov 10, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that Nancy Pecota , Aradigm's Chief Financial Officer, will present an overview of the Company at the Stifel 2016 Healthcare Conference at the Lotte New York Palace Hotel in New York, New York on
Aradigm Announces Third Quarter 2016 Financial Results
Nov 09, 2016
HAYWARD, Calif. --(BUSINESS WIRE)-- Aradigm Corporation ( NASDAQ : ARDM) (the "Company") today announced financial results for the third quarter and nine months ended September 30, 2016 . Third Quarter 2016 Financial Results The Company recorded $50,000 in revenue in the third quarter of 2016
Displaying 1 - 20 of 229
CONTACT NEWS & EVENTS LEGAL SITE MAP ©2018 Aradigm Corporation. All Rights Reserved.